Oct. 16, 2009--GlaxoSmithKline (GSK) announced today that the U.S. FDA has approved CERVARIX® [Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant] for the prevention of cervical pre-cancers and cervical cancer associated with oncogenic human papillomavirus (HPV) types 16 and 18 for use in girls and young women (aged 10-25).
The details can be read here.
1 comment:
Dear Webmaster,
Pathology.org is the largest up to date informational database consisting of general health and disease information. The only way to combat disease and promote healthy living is to provide the public current information on health and diseases. Pathology.org consists of breaking news in the health world and offers the information needed to take preventive and combative measures to fight disease. Your website seems to be a very credible resource and would beneficial to us in the fight to combat the contraction and spread of disease. You can aid us in this fight by simply putting a banner or link up for us, making our site available to your vast public. I have included the code for the banner within this email showing you exactly what this banner will look like. Thank you for your time, effort, and work you have done, we look forward to any thoughts you may have.
Pathology.org is awarding you as top resource and if you would like to get the banner, please email me back with the subject line as your URL to avoid Spam and also to make sure that you only get the banner.
Post a Comment